ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause


23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment.

The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of fezolinetant (Astellas) for moderate to severe vasomotor symptoms associated with menopause.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder